New York biotech scores win as Fed Circ upholds preliminary injunction against Celltrion's biosimilar launch | Ruling follows ...

In a report released today, Tyler Van Buren from TD Cowen maintained a Buy rating on Regeneron (REGN – Research Report), with a price target of ...

Regeneron Pharmaceuticals has received a positive opinion from the European Medicines Agency’s human medicines committee for ...

Wen is among the 40 finalists heading to Washington D.C. Thursday to present their projects to panels of experts. The winners ...

Vertex Pharmaceuticals has outperformed the broader healthcare sector over the past year. Despite a 6.3% drop from its ...

Mutual of America Capital Management LLC reduced its stake in Regeneron Pharmaceuticals by 3.4%, selling 457 shares in Q4.

Shares of Regeneron Pharmaceuticals Inc. REGN rose 1.73% to $687.15 Wednesday, on what proved to be an all-around favorable ...

The Federal Circuit upheld a preliminary injunction blocking the launch of a Celltrion Inc. biosimilar version to Regeneron ...

On Feb. 18, 2025, the U.S. Court of Appeals for the First Circuit adopted the “but for” causality standard for violations of the federal ...

On February 18, 2025, in United States v. Regeneron Pharmaceuticals, the First Circuit held that to establish civil liability under the False ...